Literature DB >> 20083666

Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Randal K Gregg1, Lisa Nichols, Yiming Chen, Bao Lu, Victor H Engelhard.   

Abstract

Generalized vitiligo is thought to have an autoimmune etiology and has been correlated with the presence of CD8 T cells specific for melanocyte differentiation Ag. However, limited animal models for the disease have hampered its understanding. Thus, we generated TCR transgenic mice that recognize an epitope of the melanocyte protein, tyrosinase. These animals develop vitiligo with strikingly similar characteristics to the human disease. Vitiligo develops temporally and spatially, with juvenile lesions forming bilaterally in head and facial areas, and only arising later in the body of adult animals. Vitiligo is entirely dependent on CD8 T cells, whereas CD4 T cells exert a negative regulatory effect. Importantly, CD8 T cells can be pervasively present in the skin in the steady state without inducing vitiligo in most areas. This points to developmental differences in melanocyte susceptibility and/or immunological effector mechanisms over time, or in different body locations. Disease is strongly dependent on both IFN-gamma and CXCR3, whereas dependence on CCR5 is more limited, and both CCR4 and perforin are dispensable. Genetic ablation of CXCR3 or IFN-gamma also resulted in scarce CD8 T cell infiltration into the skin. Our results identify unexpected complexity in vitiligo development and point toward possible therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083666      PMCID: PMC2887735          DOI: 10.4049/jimmunol.0902778

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

Review 1.  Autoimmune etiology of generalized vitiligo.

Authors:  I Caroline Le Poole; Rosalie M Luiten
Journal:  Curr Dir Autoimmun       Date:  2008

2.  Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.

Authors:  F Bernassola; C Scheuerpflug; I Herr; P H Krammer; K M Debatin; G Melino
Journal:  Cell Death Differ       Date:  1999-07       Impact factor: 15.828

Review 3.  Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.

Authors:  V H Engelhard; T N Bullock; T A Colella; D W Mullins
Journal:  Cancer J       Date:  2000-05       Impact factor: 3.360

Review 4.  Evidence for an autoimmune pathogenesis of vitiligo.

Authors:  Katia Ongenae; Nanny Van Geel; Jean-Marie Naeyaert
Journal:  Pigment Cell Res       Date:  2003-04

5.  CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.

Authors:  Teresa Lambe; Janson C H Leung; Tiphaine Bouriez-Jones; Karlee Silver; Kimmo Makinen; Tanya L Crockford; Helen Ferry; John V Forrester; Richard J Cornall
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 6.  Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades.

Authors:  A K Hubbard; R Rothlein
Journal:  Free Radic Biol Med       Date:  2000-05-01       Impact factor: 7.376

7.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

8.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

Review 9.  Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.

Authors:  Victor H Engelhard; Timothy N J Bullock; Teresa A Colella; Stacey L Sheasley; David W Mullins
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

10.  High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.

Authors:  G S Ogg; P Rod Dunbar; P Romero; J L Chen; V Cerundolo
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  47 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

Review 3.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 4.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

5.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

6.  Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Authors:  Jonathan M Eby; Hee-Kap Kang; Jared Klarquist; Shilpak Chatterjee; Jeffrey A Mosenson; Michael I Nishimura; Elizabeth Garrett-Mayer; B Jack Longley; Victor H Engelhard; Shikhar Mehrotra; I Caroline Le Poole
Journal:  Pigment Cell Melanoma Res       Date:  2014-07-21       Impact factor: 4.693

7.  Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.

Authors:  S You; Y-H Cho; J-S Byun; E-C Shin
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

8.  Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Authors:  Jeffrey A Mosenson; Andrew Zloza; John D Nieland; Elizabeth Garrett-Mayer; Jonathan M Eby; Erica J Huelsmann; Previn Kumar; Cecele J Denman; Andrew T Lacek; Frederick J Kohlhapp; Ahmad Alamiri; Tasha Hughes; Steven D Bines; Howard L Kaufman; Andreas Overbeck; Shikhar Mehrotra; Claudia Hernandez; Michael I Nishimura; Jose A Guevara-Patino; I Caroline Le Poole
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

Review 9.  Innate immune mechanisms in vitiligo: danger from within.

Authors:  Jillian M Richmond; Michael L Frisoli; John E Harris
Journal:  Curr Opin Immunol       Date:  2013-11-12       Impact factor: 7.486

10.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.